Tags: Drug.
Omigapil (TCH346 or CGP3466) is a drug that was developed by Novartis and tested in clinical trials for its ability to help treat Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). The development for PD and ALS have been terminated due to lack of benefit but Santhera Pharmaceuticals bought the compound for development for the treatment of congenital muscular dystrophy (CMD).Omigapil was first synthesized at Ciba-Geigy Basel Switzerland.
